Quality Risk Management in ATMP Manufacturing: EMA’s Guidance Quality Risk Management in ATMP Manufacturing: EMA’s Guidance The increasing complexity of Advanced Therapy Medicinal Products (ATMPs) presents unique challenges in Quality Risk Management (QRM) during manufacturing. This article outlines a step-by-step guide compliant with the European Medicines Agency (EMA) guidance for QRM, serving as a practical resource for US-based regulatory affairs professionals, particularly those focused on the manufacturing of ATMPs. By following this structured approach, professionals can enhance their understanding of EMA ATMP regulatory consulting practices and ensure effective compliance with Good Manufacturing Practices (GMP). Step 1: Understanding the Regulatory Framework…

Annex 2 GMP for ATMPs: Cleanroom, Aseptic, and Environmental Control Requirements Annex 2 GMP for ATMPs: Cleanroom, Aseptic, and Environmental Control Requirements This tutorial provides a comprehensive, step-by-step approach to understanding and implementing the GMP requirements specific to Advanced Therapy Medicinal Products (ATMPs) as delineated in Annex 2 of the EU Guidelines for Good Manufacturing Practices. Special emphasis is placed on cleanroom conditions, aseptic processing environments, and environmental control measures necessary for ensuring product quality and safety. This guide is essential for professionals involved in regulatory affairs, clinical development, and quality assurance for ATMPs in the United States. Step 1:…

GMP Compliance for ATMPs: EU vs US Regulatory Expectations GMP Compliance for ATMPs: EU vs US Regulatory Expectations As the field of Advanced Therapy Medicinal Products (ATMPs) continues to expand, understanding the regulatory landscape for Good Manufacturing Practices (GMP) compliance in both the US and EU is crucial for organizations involved in the development and production of these innovative therapies. This article provides a thorough, step-by-step tutorial guide on ATMP GMP compliance, highlighting the key differences and similarities between the US and EU regulations, and offering practical actions and documentation expectations. Step 1: Understanding ATMP Classification and Regulatory Framework The…

How FDA Evaluates Potency Assays for Cell/Gene Therapies in : Reviewer Questions to Preempt How FDA Evaluates Potency Assays for Cell/Gene Therapies in : Reviewer Questions to Preempt Introduction to Potency Assays in ATMPs The field of Advanced Therapy Medicinal Products (ATMPs) has revolutionized treatment paradigms with therapies that often involve complex interactions at the cellular and genetic level. Potency assays play a crucial role in determining the therapeutic efficacy of these products. The FDA evaluates these assays rigorously, and understanding this evaluation process is essential for developers and regulatory professionals. This article aims to guide you through the steps…

FDA LTFU Requirements for ATMPs in : 15-Year Follow-Up Planning and Data Systems FDA LTFU Requirements for ATMPs in : 15-Year Follow-Up Planning and Data Systems Step 1: Understanding LTFU Requirements for ATMPs Long-term follow-up (LTFU) is an essential component of the regulatory framework for Advanced Therapy Medicinal Products (ATMPs) as mandated by the FDA. The FDA has recognized that due to the nature of ATMPs, which may involve cell and gene therapies, there might be long-lasting effects that require monitoring over extended periods, often up to 15 years. Thus, developers must account for these LTFU requirements early in their…

Enforcement Discretion and Minimal Manipulation: US Strategy for Borderline ATMP Products in 2023 Enforcement Discretion and Minimal Manipulation: US Strategy for Borderline ATMP Products in 2023 The regulatory landscape for Advanced Therapy Medicinal Products (ATMPs) in the United States can be complex and multifaceted, particularly concerning enforcement discretion and the concept of minimal manipulation. This step-by-step guide aims to provide regulatory affairs professionals, clinical development teams, and quality assurance experts with clear actions and documentation expectations for navigating the specific challenges associated with borderline ATMP products within the framework provided by the FDA, particularly under the context of the Regenerative…

Accelerated Approval for ATMPs in 2024: Evidence Planning and Postmarketing Commitments Accelerated Approval for ATMPs in 2024: Evidence Planning and Postmarketing Commitments The regulatory landscape surrounding Advanced Therapy Medicinal Products (ATMPs) has evolved considerably, with the FDA introducing pathways to streamline their approval process. In 2024, understanding the Accelerated Approval pathway is vital for stakeholders aiming to expedite the transition from laboratory innovation to patient access. This article serves as a comprehensive step-by-step guide to navigating ATMP regulatory consulting, focusing on evidence planning and postmarketing commitments. Step 1: Understanding the Accelerated Approval Pathway The Accelerated Approval pathway, introduced by the…

CMC Review Hotspots for ATMP BLAs in 2023: FDA Expectations for Control Strategy CMC Review Hotspots for ATMP BLAs in 2023: FDA Expectations for Control Strategy Advanced Therapy Medicinal Products (ATMPs), including gene therapies, tissue-engineered products, and somatic cell therapies, present unique regulatory challenges and opportunities. In 2023, the FDA continues to refine expectations for Chemistry, Manufacturing, and Controls (CMC) aspects of Biologics License Applications (BLAs) for these innovative therapies. This article serves as a comprehensive step-by-step tutorial for industry professionals navigating CMC review hotspots in the context of ATMP BLAs, with a focus on practical actions and documentation expectations…

FDA INTERACT and Pre-IND Meeting Strategy for ATMPs in : Briefing Book Template FDA INTERACT and Pre-IND Meeting Strategy for ATMPs in : Briefing Book Template The development of Advanced Therapy Medicinal Products (ATMPs), particularly gene therapies, presents unique regulatory challenges and opportunities. Navigating the regulatory landscape requires effective planning and strategic engagement with regulatory authorities. This guide outlines a step-by-step approach to utilizing the FDA’s INTERACT and Pre-Investigational New Drug (Pre-IND) meeting strategies for ATMPs, detailing the preparation of a briefing book and the crucial elements for successful regulatory dialogue. Step 1: Understanding the Regulatory Framework for ATMPs Before…

RMAT Designation Consulting in 2023: Qualification Criteria, Benefits, and Common Deficiencies RMAT Designation Consulting in 2023: Qualification Criteria, Benefits, and Common Deficiencies The landscape of drug development, particularly within the scope of Advanced Therapy Medicinal Products (ATMPs) such as gene therapies, is ever-evolving. For stakeholders in the pharmaceutical sector, understanding the Regenerative Medicine Advanced Therapy (RMAT) designation is critical. This article serves as a comprehensive step-by-step guide for regulatory professionals focusing on RMAT designation consulting, detailing the qualification criteria, associated benefits, and common deficiencies encountered throughout the submission process. Step 1: Understanding RMAT Designation and Its Purpose Before diving into…